

PRESS RELEASE

Strategic collaboration between BRAIN and BioSilta to co-develop high throughput enzyme expression and discovery technologies

Zwingenberg (D) and Oulu (Fi), April 28, 2008: The White Bio-tech company BRAIN AG located in Zwingenberg, Germany and the biotechnology start-up BioSilta Oy of Oulu, Finland entered a strategic collaboration. The goal of this collaboration is to co-develop and optimize microwell plate based high cell density protein expression and high throughput enzyme discovery technologies through the application of the advanced cell culture technology platform EnBase. In this strategic collaboration, EnBase shall be implemented into application oriented processes to accelerate enzyme discovery and improve expression of enzymes used for industrial applications.

Under the terms of the agreement, BRAIN has access to the EnBase technology, characterised by enzyme based substrate delivery from a polymer layer to the cultivation medium for high throughput screening with expression libraries and commercially relevant microbial host strains. BioSilta gets access to application-relevant process developments on high throughput enzyme discovery and protein expression.

Contact:

BzRzAzlN AG
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Phone: +49-6251-9331-16
Fax.: +49-6251-9331-11
E-Mail: ml@brain-biotech.de
www.brain-biotech.de

BioSilta Oy
Russell Golson
FI-90014
Oulu, Finland

Phone: +35885532361
E-Mail: russell.golson@biosilta.com
www.biosilta.com

B•R•A•I•N



"We are delighted that BRAIN as a leading European white biotech company will use our EnBase technology and within the collaboration will help us to develop our system towards application-oriented enzyme screenings", states Russell Golson, CEO of BioSilta Oy. "We enable customers to improve the yield and the quality of simple bacterial cultures. You can obtain up to 50 times more bacteria and consequently higher amount of recombinant proteins in the same volume with our innovative EnBase products."

"Our EvoSolution[®] technology platform makes it possible to identify candidate enzymes and biocatalysts. Through the last ten years BRAIN built up a broad application knowledge in Metagenome[®] handling and projects for the identification and development of innovative enzymes and biocatalysts," says Dr. Jürgen Eck, Chief Technology Officer at BRAIN AG. "We are convinced that the striking EnBase technology of BioSilta will broaden our technology platform and will be of help to increase screening sensitivity leading to higher hit rates and to speed-up development cycles for industrial enzymes and biocatalysts."

About BRAIN

BRAIN is a research and development company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical as well as the food and cosmetics industries. In a unique approach to the discovery and production of new biological compounds and biocatalysts, the company harnesses creative solutions from nature's untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. BRAIN was founded in 1993, currently employs 65 highly qualified people and has developed into one of Europe's leading white (industrial) biotech companies.

www.brain-biotech.de

About BioSilta

BioSilta is an ambitious biotech company based in Oulu, Finland – a region already renowned as home to Polar Electro and other leading wireless technologies – and now emerging as an international bioscience hub. BioSilta was formed in 2007 by internationally renowned Bio-scientist, Peter Neubauer. The pioneering company has developed EnBase™ – a unique cell cultivation kit, especially suited towards automated application, which gives researchers a bigger and better harvest than traditional laboratory methods. BioSilta continues to develop uses of enzyme and biocatalytic activity to advance cell culture technology across a greater range of product formats and bacteria.


The business has the backing of Inveni Capital, a Nordic-German venture capitalist investing in biotechnology start-ups.

www.biosilta.com

Pictures



High throughput screening of BRAIN's large Metagenome® library.
©BRAIN AG; Reprint permitted with byline



Picking and spotting robot for handling of large numbers of Metagenome® clones.
©BRAIN AG; Reprint permitted with byline

Pictures and text can be downloaded under: www.brain-biotech.de/news